

<https://helda.helsinki.fi>

Fourteen-Year Trends in the Use of Psychotropic Medications, Opioids, and Other Sedatives Among Institutionalized Older People in Helsinki, Finland

Roitto, Hanna-Maria

2019-03

Roitto , H-M , Kautiainen , H , Aalto , U L , Ohman , H , Laurila , J & Pitkala , K H 2019 , ' Fourteen-Year Trends in the Use of Psychotropic Medications, Opioids, and Other Sedatives Among Institutionalized Older People in Helsinki, Finland ' , Journal of the American Medical Directors Association , vol. 20 , no. 3 , pp. 305-311 . <https://doi.org/10.1016/j.jamda.2018.12.022>

<http://hdl.handle.net/10138/321650>

<https://doi.org/10.1016/j.jamda.2018.12.022>

cc_by_nc_nd

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

1 **14-Year Trends in the Use of Psychotropic Medications, Opioids, and Other Sedatives among**
2 **Institutionalized Older People in Helsinki, Finland**

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 *Objectives:* The use of psychotropic drugs in long-term care (LTC) is very common, despite their
28 known adverse effects. The prevalence of opioid use is growing among older adults. This study
29 aimed to investigate trends in the prevalence of psychotropics, opioids, and sedative load in a LTC
30 setting over a 14-year period. We also explored the interaction of psychotropic and opioid use
31 according to residents' dementia status in nursing home (NH) and assisted living facility (ALF)
32 settings.

33 *Design:* Four cross-sectional studies.

34 *Setting:* institutional settings in Helsinki, Finland.

35 *Participants:* Older residents in NHs in 2003 (n=1987), 2011 (n=1576), and 2017 (n=791) and in
36 ALFs in 2007 (n=1377), 2011 (n=1586), and 2017 (n=1624).

37 *Measures:* Comparable assessments were conducted among LTC residents at four time-points over
38 14 years. The prevalence of regular psychotropics, opioids, and other sedatives and data on
39 demographics and diagnoses were collected from medical records.

40 *Results:* Disabilities and severity of dementia increased in both settings over time. The prevalence
41 of all psychotropics decreased significantly in NHs (from 81% in 2003 to 61% in 2017), whereas in
42 ALFs there was no similar linear trend (65% in 2007 and 64% in 2017). There was a significant
43 increase in the prevalence of opioids in both settings, being 30% in NHs and 22% in AFLs in 2017.
44 Residents with dementia used less psychotropics and opioids than those without dementia in both
45 settings and at each time-point.

46 *Conclusions/Implications:* NHs show a favorable trend in psychotropic drug use, but the rates of
47 psychotropic use remain high in both NHs and ALFs. In addition, the rates of opioid use have
48 almost tripled, leading to a high sedative load among LTC residents. Clinicians should carefully
49 consider the risk-to-benefit ratio when prescribing in LTC.

50

51 **Introduction**

52

53 The use of psychotropic drugs in long-term care (LTC) is very common.¹ In studies published from
54 2004 to 2017, the prevalence of use of any psychotropic drug has varied between 52% and 80% in
55 nursing homes (NHs)²⁻⁶ and between 53% and 68% in assisted living facilities (ALFs)^{7,8}. The
56 prevalence of any psychotropic is higher among LTC residents with dementia than among their
57 peers with normal cognition.^{9,10} There have been concerns of the potential adverse effects related to
58 psychotropic medication such as falls and cognitive decline.^{11,12} Higher use of healthcare services
59 and greater mortality have also been suggested.^{13,14} Psychotropic use has been associated with
60 lower quality of life.¹⁵ Few studies have examined the long-term trends in the use of psychotropics
61 in LTC settings. In NHs of the United States, use of antipsychotics decreased after OBRA 87,¹⁶
62 whereas the use of antidepressants increased between 1996 and 2006.¹⁷ In 2018 data from the
63 National Partnership Program in the United States showed a significant reduction of antipsychotic
64 use between 2011-2018 being 14.8% nationwide¹⁸. In Finnish NHs the use of antipsychotics,
65 anxiolytics, and hypnotics decreased between 2003 and 2011.¹⁹ However, less is known about the
66 trends in later years.

67 The prevalence of opioid use has been growing in the older population,²⁰ and also in NHs over the
68 years.^{19,21} In a recent study, the use of opioids has not decreased from 2007 to 2016 among older
69 people, and their use is highest among disabled Medicaid beneficiaries.²² High use could be
70 problematic because older adults are prone to falls, cognitive decline, and delirium.²³⁻²⁵

71 Concomitant use of psychotropic medications and opioids may result in a high sedative load
72 among vulnerable LTC residents. The aim of this study was to examine trends in prevalence of
73 psychotropic medications and opioids in institutionalized older adults in Helsinki over a 14-year
74 period. We also explored the interaction of psychotropic and opioid use according to residents'
75 dementia status in NH and ALF settings.

76 **Methods**

77

78 *Study participants*

79 This study combined data from four comparable cross-sectional studies exploring medication use
80 and nutrition in institutional settings in Helsinki. The studies were conducted among all NH
81 residents of Helsinki in 2003 (n=1987), 2011 (n=1576), and 2017 (n=791) and among all ALF
82 residents of Helsinki in 2007 (n=1377), 2011 (n=1586), and 2017 (n=1624). All residents aged 65
83 years and older were invited to participate. The 2003, 2011, and 2017 samples comprised 94%,
84 81%, and 68% of the total NH population, and the 2007, 2011, and 2017 samples 66%, 64%, and
85 62% of the total ALF population, respectively. The nonparticipants were those suffering from
86 moderate-severe dementia (CDR 2-3) and not having a close proxy to give informed consent,
87 refusals, or those not providing a complete medication list.

88

89 In Finland, ALFs provide round the clock care with a registered nurse in charge. This is similar to
90 the care provided in NHs, but ALFs are designed to resemble residents' own home environment to a
91 greater extent. ALFs include both apartments and group homes for people with dementia. However,
92 the number of registered nurses is lower in ALFs than in traditional NHs. The number of NH beds
93 in Helsinki has significantly declined from 2003 to 2017, and this has been compensated by an
94 increase in the number of ALF beds. The national recommendation for minimum staffing levels in
95 24-hour care is 0.6 employees per resident in NHs and 0.5 in ALFs.

96

97 *Measures*

98

99 All medications were classified using the Anatomical Therapeutic Chemical (ATC) classification
100 system.²⁶ Psychotropic medications included antipsychotics (N05A), antidepressants (N06A),

101 anxiolytics (N05B), and hypnotics and sedatives (N05C). Opioids (N02A) were further categorized
102 as weak opioids (codeine, buprenorphine, tramadol) and strong opioids (morphine, fentanyl,
103 oxycodone). The use of paracetamol (N02BE01) and nonsteroidal anti-inflammatory drugs
104 (NSAIDs) (M01A) was also included to illustrate the overall use of pain medication. In addition, we
105 report the use of Alzheimer medication (N06D), including cholinesterase inhibitors (N06DA)
106 and/or memantine (N06DX01), because they are often used for neuropsychiatric symptoms
107 alternatively to psychotropics.²⁷ In addition to psychotropics and opioids, we defined, for the
108 purpose of the analysis, also other medications that contribute to sedative load, including pregabalin
109 (N03AX16), gabapentin (N03AX12), carbamazepine (N03AF01), oxcarbazepine (N03AF02), and
110 valproic acid (N03AG01). Medication use was considered regular if there was a documented
111 regular sequence of administration. Only regularly used medications were considered when
112 comparing the prevalence at each time-point. Medication use was reported as using/not using.
113 Dosages were not calculated.

114

115 Data on medication use, diagnoses, and demographic factors were collected from medical records.
116 The Charlson Comorbidity Index²⁸ was used to calculate each resident's burden of comorbidity. We
117 trained thoroughly nurses in each setting to collect data and perform the assessments. The nurses
118 used Clinical Dementia Rating (CDR)²⁹ to grade the severity of dementia and Mini Nutritional
119 Assessment (MNA)³⁰ to assess and grade each resident's nutritional state. Resident's mobility was
120 assessed by the MNA item and categorized to either 0="unable to get out of a bed, a chair,
121 or a wheelchair without the assistance of another person" or 1="able to get out of bed or a chair
122 without help".

123

124

125

126 *Statistics*

127 Significance for the unadjusted hypothesis of linearity between cohorts was evaluated by using the
128 Cochran-Armitage test for trend or analysis of variance with an appropriate contrast.
129 Number of medications used was calculated using a Poisson regression model and proportion of
130 opioids users was evaluated using a logistic model. The models included gender, age, Charlson
131 comorbidity index, and ability to move independently as covariates. The bootstrap method was used
132 when the theoretical distribution of the test statistics was unknown or in the case of violation of
133 assumptions (e.g. non-normality). The normality of variables was evaluated with the Shapiro-Wilk
134 W-test. All analyses were performed using STATA 15.1 (StataCorp, College Station, TX, USA).

135 *Statement of ethics*

136

137 The study protocol was approved by the Ethics Committee of the University of Helsinki. Written
138 informed consent was obtained from each participant and in case of significant cognitive decline
139 (CDR 2 or 3) from their closest proxy.

140

141 **Results**

142 NH and ALF residents were more disabled in their mobility and had more often dementia in the
143 latter cohorts (Tables 1 and 2). The severity of cognitive decline increased over time in both settings
144 according to the CDR memory item. The proportion of males increased over time in both facilities.
145 Mean age, comorbidities, or nutritional status did not change significantly over time.

146 The prevalence of psychotropic medication use declined significantly in the NHs ($p < 0.001$),
147 whereas in ALFs there was no linear trend ($p = 0.15$). The prevalence of regular psychotropic
148 medication use in NHs fell from 81.3 % in 2003 to 60.9% in 2017. In ALFs, the prevalence
149 remained more stable, being 64.6% in 2007 and 63.6% in 2017. In NHs, the use of antipsychotic
150 medication dropped from 42.7% to 32.7%, whereas in ALFs the use of antipsychotic medication

151 increased from 27.3% to 34.0%. Also the use of antidepressants dropped from 44.9% to 32.7% in
152 NHs. In ALFs, the prevalence of antidepressants increased from 39.3% to 46.3% in 2011 and
153 dropped again to 37.5% in 2017. The prevalence of anxiolytic use dropped from 40.9 % to 14.4% in
154 NHs, and in ALFs from 24.1% to 9.6%. The use of hypnotics also decreased significantly in NHs
155 from 11.3% to 6.1%, whereas in ALFs there was a significant increase from 10.2% to 17.2%.

156 The prevalence of regular opioid use increased linearly in both NHs and ALFs over the years
157 ($p<0.001$). In NHs, the prevalence of regular opioid use increased from 11.7% in 2003 to 30.2% in
158 2017. In ALFs, the increase was from 8.6% in 2007 to 21.6% in 2017. The largest increase in
159 prevalence was observed in strong opioids in NHs, where the prevalence increased from 1.9% to
160 14.9%.

161 The use of NSAIDs decreased significantly in both groups, being minimal in 2017; 0.8% in NHs
162 and 0.5% in ALFs. Paracetamol was widely used and its prevalence increased significantly in NHs
163 from 34.3% in 2003 to 51.6% in 2017, whereas its use in ALFs did not change significantly, being
164 38.6% in 2017. The prevalence of pregabalin or gabapentin use in NHs increased from 0.6% to
165 9.1%. In ALFs, the corresponding increase was from 2.2% to 6.9%. The prevalence of Alzheimer
166 medication increased significantly for both groups ($p<0.001$). One in three NH residents and half of
167 ALF residents were administered Alzheimer medication in 2017.

168 The overall sedative load decreased significantly in NH residents ($p<0.001$), from 84.6% in 2003 to
169 69.1% in 2017. In ALFs, no significant change occurred in the prevalence of sedative medication.

170 When the psychotropic users were stratified according to diagnosis of dementia, in NHs both people
171 with and without dementia showed significant decrease in the prevalence of psychotropic use over
172 the 14-year follow-up ($p<0.001$ for cohort), whereas people with dementia used less psychotropics
173 ($p<0.001$ for dementia), and among them the use decreased more rapidly ($p<0.001$ for interaction)
174 (Figure 1a). There was no similar interaction in ALFs ($p<0.001$ for cohort, $p=0.004$ for dementia,

175 $p=0.41$ for interaction) (Figure 1a). In NHs the whole cohort showed significant decrease in the use
176 of antipsychotics over the 14-year follow-up ($p<0.001$ for cohort), whereas people with dementia
177 used less antipsychotics than those without dementia ($p=0.026$ for dementia). There was no
178 interaction ($p=0.060$ for interaction) (Figure 1b). In ALFs the use of antipsychotics increased over
179 time and people with dementia used more antipsychotics than those without dementia ($p<0.001$ for
180 cohort, $p<0.001$ for dementia and $p=0.024$ for interaction) (Figure 1b). In NHs the whole cohort
181 showed significant decrease in the use of anxiolytics and hypnotics over the 14-year follow-up
182 ($p<0.001$ for cohort), whereas people with dementia used less anxiolytics and hypnotics ($p<0.001$
183 for dementia). There was no interaction among people with and without dementia ($p=0.38$ for
184 interaction) (Figure 1c). In ALFs the use of anxiolytics and hypnotics also decreased over time and
185 people with dementia used less anxiolytics and hypnotics than those without dementia ($p<0.001$ for
186 cohort, $p<0.001$ for dementia and $p=0.37$ for interaction) (Figure 1b). In NHs the whole cohort
187 showed significant decrease in the use of antidepressants over the 14-year follow-up ($p<0.001$ for
188 cohort). People with dementia used less antidepressants than those without dementia ($p<0.001$ for
189 dementia). People without dementia showed more rapid decrease in antidepressants than those with
190 dementia ($p=0.0015$ for interaction) (Figure 1d). In ALFs the use of antidepressants showed an
191 overall trend of increase in the whole cohort ($p<0.001$ for cohort). People with dementia used less
192 antidepressants than those without dementia ($p=0.022$ for dementia). There was no interactions
193 ($p=0.35$ for interaction) (Figure 1d).

194 When the opioids users in NHs were stratified according to diagnosis of dementia, the whole cohort
195 showed significant increase in the use of opioids over the 14-year period ($p<0.001$ for cohort).
196 People with dementia used less opioids ($p<0.001$ for dementia), and the use increased more rapidly
197 among them compared to those without dementia ($p<0.001$ for interaction) (Figure 2). In ALFs, the
198 residents with dementia used less opioids, but the use increased over time; there was, however, no
199 interaction ($p<0.001$ for cohort, $p<0.001$ for dementia, $p=0.65$ for interaction). In NHs, both groups

200 showed significant decreases in the prevalence of overall sedative medication use over the 14-year
201 follow-up ($p < 0.001$ for dementia, $p < 0.001$ for cohort, $p < 0.039$ for interaction) (Figure 3). In ALFs,
202 people with dementia used less sedatives ($p < 0.001$ for dementia), with the use increasing
203 significantly over time ($p < 0.001$), but there was no interaction ($p = 0.058$).

204

205 **Discussion**

206

207 Our study demonstrated important trends in the use of psychotropic medications and opioids over
208 the past 14 years in LTC in Helsinki. The prevalence of psychotropic medication decreased
209 significantly in NHs, but not in ALFs. There was a considerable increase in the prevalence of
210 opioids in both settings. The changes detected may partly reflect the changes in resident profile:
211 both dementia and mobility disabilities are more prevalent and more severe in latter cohorts and the
212 difference between these two settings has diminished.

213 An important strength of our study is the large sample size and comparable data at each of the four
214 time-points. Residents were assessed by well-trained nurses in 2003, 2007, 2011, and 2017 using
215 the same data collection instruments and methodology, resulting in high validity of data. Our
216 assessments were cross-sectional. We were not able to follow the same resident at different time-
217 points, because the mean time spent in LCT in Helsinki is less than two years. Another strength of
218 the study is that medication use was taken directly from each resident's medication administration
219 chart, ensuring that only medication actually taken was included in the analysis. Moreover, we only
220 considered medication that was taken regularly. However, it has been shown that psychotropic
221 medication may also be administered on a pro re nata basis, so our results might underestimate the
222 actual use of these medications.¹⁰ Another limitation is that response rates have significantly
223 decreased over the years in NHs. The non-responders are mainly people with moderate-severe
224 dementia and not having a proxy. Thus, the estimates of increases in dementia and disability are

225 probably underestimates. In addition, the organization of long-term care has changed over time
226 challenging the comparability of NHs. The number of NH beds has significantly decreased whereas
227 the increasing number of beds in ALFs have replaced them. However, all available residents living
228 in Helsinki long-term care were included.

229 The results of this study are fairly in line with other recent studies examining the growing trend of
230 opioid use in LTC.^{31, 21} However, the opioid use in LTC in Helsinki is still lower than among
231 disabled Medicaid beneficiaries in the United States (quarterly use 39%).²¹ The increased use of
232 opioids around the world may reflect the overall “opioid epidemic”, i.e. the marked rise in opioid
233 use in general populations.³² On the other hand it has also been noted that pain assessment and
234 management are suboptimal among patients with dementia in NHs.³³ At the end-of-life care the use
235 of opioids and psychotropics is often appropriate.³⁴ However, according to RAI data on the study
236 population, the number of residents in terminal care is very small (0.6%)³⁵ and has not significantly
237 increased over time. The use of other painkillers seem to become favourable since the use of
238 NSAIDs has almost disappeared and the use of paracetamol has increased. However, the fairly high
239 concomitant use of gabapentinoids may predispose residents to falls.³⁶

240 While the changes in the use of opioid medications were consistent with other recent studies, the
241 changes in the use of psychotropic medication were found to be more complex. A systematic review
242 and meta-analysis reported a small increase in antipsychotic medication in LTC residents with
243 dementia from 1991 to 2013,³⁷ whereas other studies have reported a decrease in the use of
244 antipsychotic medication, albeit an increase in the use of antidepressants.^{18,38,39} The prevalence of
245 antipsychotic use in our sample is more than double compared to the latest figures in the U.S.¹⁸

246 In our study, the use of psychotropic medication in NHs decreased significantly, but this trend was
247 not seen in ALFs. This could be partly because the residents in ALFs were more mobile, with less
248 advanced dementia, and they may have suffered more often from neuropsychiatric symptoms than

249 the residents of NHs. Another possible explanation is that in Finland the staff in NHs includes more
250 registered nurses than in ALFs, thus having a better pharmacologic education and ability to assess
251 the possible benefits and adverse effects of psychotropic medication. The training of nurses has
252 been shown to improve physicians' prescribing practices in LTC.⁴⁰ Antipsychotics are often used to
253 treat neuropsychiatric symptoms of dementia even though the evidence of their effectiveness is
254 limited⁴¹ and the guidelines suggest non-pharmacological treatments as the first line choice.⁴² Even
255 though the use of Alzheimer medication increased significantly over the years, it did not decrease
256 the use of antipsychotics in ALFs.

257 It has also been suggested that older adults with dementia may express pain as neuropsychiatric
258 symptoms, such as agitation and aggression,^{43,44} and that treating pain systematically reduces these
259 symptoms.⁴⁵ The steep rise in the use of opioids in both settings could reflect better pain recognition
260 and clinicians' efforts to optimize pain management to reduce neuropsychiatric symptoms among
261 residents with dementia. Alarming is that the concomitant use of antipsychotic medication remains
262 high and even keeps increasing at the same time in ALFs.

263 In our study, residents with dementia used less psychotropics and opioids and had a lower sedative
264 load than residents without dementia. People without dementia admitted to LTC probably suffer
265 from stroke, depression, other psychiatric illnesses, and disabling musculoskeletal diseases that
266 cause pain, increasing their use of various psychotropics.⁴⁶ People with chronic mental health
267 conditions such as schizophrenia are likely to require psychotropic medication, although the dosage
268 may need to be readjusted as they age.

269 To our knowledge, this is the first study with over 10-year follow-up investigating trends in the use
270 of both psychotropic medication and opioids among institutionalized older adults. Our study both
271 confirms earlier findings and provides novel data regarding the prevalence of psychotropic and
272 opioid use in LTC. The increasing use of Alzheimer medication or opioids has not significantly

273 decreased the use of psychotropics. Instead these medication changes have led to polypharmacy
274 among vulnerable long term care population.

275 **Conclusions/Relevance**

276 Although the prevalence of psychotropics has decreased over the last 14 years in NHs, the rates of
277 psychotropic use remain high in both NHs and ALFs. In addition, the rates of opioid use have
278 almost tripled, leading to a high sedative load among vulnerable LTC residents. Clinicians should
279 carefully consider the risk-to-benefit ratio when prescribing in LTC. Strategies for regular
280 medication reviews and deprescribing in LTC are required.

281 Another finding with practical implications is that the LTC population profile has changed over
282 time. Residents are more disabled and the severity of dementia has increased. This is key
283 information for both clinicians and policy-makers to consider when planning LTC in the future. As
284 the dementia disease progresses there are often changes in behavior implicating timely assessments
285 and adjustments in person-centered care.

286

287

288 The authors declare that they have no conflicts of interest relevant to this report.

289

290 **References**

- 291 1. Janus S, van Manen J, IJzerman M, Zuidema S. Psychotropic drug prescriptions in
292 Western European nursing homes. *Int Psychogeriatr*. 2016;11:1775-1790.
- 293 2. Hosia-Randell H, Pitkälä K. Use of Psychotropic Drugs in Elderly Nursing Home
294 Residents with and without Dementia in Helsinki, Finland. *Drugs Aging* 2005;22:793-
295 800.
- 296 3. Selbaek G, Kirkevold Ø, Engedal K. The prevalence of psychiatric symptoms and
297 behavioural disturbances and the use of psychotropic drugs in Norwegian nursing
298 homes, *Int J Geriatr Psychiatry* 2007;22:843-849.
- 299 4. Richter T, Mann E, Meyer G, et al. Prevalence of psychotropic medication use among
300 German and Austrian nursing home residents: a comparison of 3 cohorts. *J Am Med Dir*
301 *Assoc* 2012;13:187.e7–187.e13.
- 302 5. Rolland Y, Andrieu S, Crochard A, et al. Psychotropic Drug Consumption at Admission
303 and Discharge of Nursing Home Residents. *J Am Med Dir Assoc* 2012;13:407.e7 -
304 407.e12.
- 305 6. Helvik A, Šaltytė Benth J, Wu B, et al. Persistent use of psychotropic drugs in nursing
306 home residents in Norway. *BMC Geriatr* 2017;17:52.
- 307 7. Crotty M, Whitehead C, Rowett D, et al. An outreach intervention to implement
308 evidence based practice in residential care: a randomized controlled trial
309 [ISRCTN67855475]. *BMC Health Serv Res* 2004;4:6.
- 310 8. Stafford AC, Alswayan MS, Tenni, PC. Inappropriate prescribing in older residents of
311 Australian care homes. *J Clin Phar Ther* 2011;36:33-44.
- 312 9. Schulze J, van den Bussche H, Glaeske G, et al. Impact of safety warnings on
313 antipsychotic prescriptions in dementia: nothing has changed but the years and the
314 substances. *Eur Neuropsychopharmacol* 2013;23:1034-1042.

- 315 10. Allers K, Dörks M, Schmiemann G, et al. Antipsychotic drug use in nursing home
316 residents with and without dementia: keep an eye on the pro re nata medication. *Int Clin*
317 *Psychopharmacol* 2017;32:213-218.
- 318 11. Schneider LS, Dagerman K, Insel PS, et al. Efficacy and adverse effects of atypical
319 antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. *Am*
320 *J Geriatr Psychiatry* 2006;14:191-210.
- 321 12. Olazarán J, Valle D, Serra JA, et al. Psychotropic medications and falls in nursing
322 homes: a cross-sectional study. *J Am Med Dir Assoc* 2013;14:213-217.
- 323 13. Schneider LS, Dagerman KS, Insel P, et al. Risk of death with atypical antipsychotic
324 drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
325 *JAMA* 2005;294:1934-1943.
- 326 14. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated
327 with antipsychotics versus other psychiatric medications. *Am J Psychiatry*
328 2007;164:1568-1576.
- 329 15. Galik E, Resnick B. Psychotropic medication use and association with physical and
330 psychosocial outcomes in nursing home residents. *J Psychiatr Ment Health Nurs*
331 2013;20:244-252.
- 332 16. Garrard J, Chen V, Dowd B. The impact of the 1987 federal regulations on the use of
333 psychotropic drugs in Minnesota nursing homes. *Am J Public Health* 1995;85:771-776.
- 334 17. Hanlon JT, Handler SM, Castle NG. Antidepressant prescribing in US nursing homes
335 between 1996 and 2006 and its relationship to staffing patterns and use of other
336 psychotropic medications. *J Am Med Dir Assoc* 2010;11:320-324.
- 337 18. National Partnership to Improve Dementia Care in Nursing Homes: Antipsychotic
338 Medication Use Data Report. Available at:

- 339 https://www.nhqualitycampaign.org/files/Antipsychotic_Medication_Use_Report.pdf
340 Accessed on December 12, 2018.
- 341 19. Pitkala KH, Juola A, Hosia H, et al. Eight-Year Trends in the Use of Opioids, Other
342 Analgesics, and Psychotropic Medications Among Institutionalized Older People in
343 Finland. *J Am Med Dir Assoc* 2015;16:973-978.
- 344 20. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and
345 misuse of opioid analgesics from 2004 to 2011. *Pain Physician* 2014;17:E119-E128.
- 346 21. La Frenais FL, Bedder R, Vickerstaff J, et al. Temporal Trends in Analgesic Use in
347 Long-Term Care Facilities: A Systematic Review of International Prescribing. *Am*
348 *Geriatr Soc* 2018;66:376-382.
- 349 22. Jeffery MM, Hooten WM, Henk HJ, et al. Trends in opioid use in commercially insured
350 and Medicare Advantage populations in 2007-16: retrospective cohort study, *BMJ*
351 2018;362:k2833.
- 352 23. Wright RM, Roumani YF, Boudreau R, et al. Effect of central nervous system
353 medication use on decline in cognition in community-dwelling older adults: findings
354 from the Health, Aging And Body Composition Study. *J Am Geriatr Soc* 2009;57:243-
355 250.
- 356 24. Laurila JV, Laakkonen ML, Tilvis RS, et al. Predisposing and precipitating factors for
357 delirium in a frail geriatric population. *J Psychosom Res* 2008;65:249-254.
- 358 25. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid
359 therapy for chronic pain: a systematic review for a National Institutes of Health
360 Pathways to Prevention Workshop. *Ann Intern Med* 2015;162:276-286.
- 361 26. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical
362 Therapeutic Chemical Classification System. ATC/DDD Index 2018. Available at:
363 https://www.whocc.no/atc_ddd_index/. Accessed on August 30, 2018.

- 364 27. Memory Disorders. Current Care Guidelines. Working group appointed by the Finnish
365 Medical Society Duodecim, Societas Gerontologica Fennica, Finnish Geriatricians, the
366 Finnish Neurological Society, Finnish Psychogeriatric Association and the Finnish
367 Association for General Practice. Available at:
368 <http://www.kaypahoito.fi/web/kh/suosituksset/suositus?id=hoi50044>. Accessed on
369 August 30, 2018.
- 370 28. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic
371 comorbidity in longitudinal studies: development and validation. *J Chronic Dis*
372 1987;40:373-383.
- 373 29. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of
374 dementia. *Br J Psychiatry* 1982;140:566-572.
- 375 30. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The Mini
376 Nutritional Assessment. *Clin Geriatr Med* 2002;18:737-757.
- 377 31. Sandvik R, Selbaek G, Kirkevold O, et al. Analgesic prescribing patterns in Norwegian
378 nursing homes from 2000 to 2011: trend analyses of four data samples. *Age Ageing*
379 2016;45:54-60.
- 380 32. Humphreys K. Avoiding globalisation of the prescription opioid epidemic. *Lancet*
381 2017;390:437-439.
- 382 33. Lichtner V, Dowding D, Esterhuizen P, et al. Pain assessment for people with dementia:
383 a systematic review of systematic reviews of pain assessment tools. *BMC Geriatr*
384 2014;14:138.
- 385 34. Jansen K, Haugen DF, Pont L, Ruths S. Safety and Effectiveness of Palliative Drug
386 Treatment in the Last Days of Life-A Systematic Literature Review. *J Pain Symptom*
387 *Manage.* 2018;55:508-521.e3.

- 388 35. Laakkonen ML, Finne-Soveri UH, Noro A, et al. Advance orders to limit therapy in 67
389 long-term care facilities in Finland. *Resuscitation* 2004;61:333-339.
- 390 36. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in
391 chronic low back pain: A systematic review and meta-analysis of randomized controlled
392 trials. *PLoS Medicine*. 2017;14:e1002369.
- 393 37. Kirkham J, Sherman C, Velkers C, et al. Antipsychotic Use in Dementia: Is There a
394 Problem and Are There Solutions? *Can J Psychiatry*. 2017;62:170-181.
- 395 38. Ruths S, Sørensen PH, Kirkevold Ø, et al. Trends in psychotropic drug prescribing in
396 Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts, *Int J Geriatr
397 Psychiatry* 2013;28:868-876.
- 398 39. Vasudev A, Shariff SZ, Liu K, et al. Trends in Psychotropic Dispensing Among Older
399 Adults with Dementia Living in Long-Term Care Facilities: 2004-2013, *Am J Geriatr
400 Psychiatry* 2015;23:1259-1269.
- 401 40. Pitkälä KH, Juola AL, Kautiainen H, et al. Education to reduce potentially harmful
402 medication use among residents of assisted living facilities: a randomized controlled
403 trial. *J Am Med Dir Assoc* 2014;15:892-898.
- 404 41. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric
405 symptoms of dementia: a review of the evidence. *JAMA* 2005;293:596-608.
- 406 42. American Geriatrics Society: Ten Things Clinicians and Patients Should Question.
407 Available at: [http://www.choosingwisely.org/wp-content/uploads/2015/02/AGS-
408 Choosing-Wisely-List.pdf](http://www.choosingwisely.org/wp-content/uploads/2015/02/AGS-
408 Choosing-Wisely-List.pdf). Accessed on December 12, 2018.
- 409 43. Tosato M, Lukas A, van der Roest HG, et al. Association of pain with behavioral and
410 psychiatric symptoms among nursing home residents with cognitive impairment: results
411 from the SHELTER study. *Pain* 2012;153:305-310.

412 44. Rajkumar AP, Ballard C, Fossey J, et al. Epidemiology of Pain in People With Dementia
413 Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications. J
414 Am Med Dir Assoc 2017;18:453.e1-453.e6.

415 45. Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural
416 disturbances in residents of nursing homes with dementia: cluster randomised clinical
417 trial. The BMJ 2011;343:d4065.

418 46. Aalto UL, Roitto HM, Finne-Soveri H et al. Use of Anticholinergic Drugs and its
419 Relationship With Psychological Well-Being and Mortality in Long-Term Care
420 Facilities in Helsinki. J Am Med Dir Assoc. 2018;19:511-515.

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437 Figure 1a. Mean number of psychotropics used by NH and ALF residents with and without
438 dementia from 2003 to 2017.

439

440 Figure 1b. Mean number of antipsychotics used by NH and ALF residents with and without
441 dementia from 2003 to 2017.

442

443 Figure 1c. Mean number of anxiolytics and hypnotics used by NH and ALF residents with and
444 without dementia from 2003 to 2017.

445

446 Figure 1d. Mean number of antidepressants used by NH and ALF residents with and without
447 dementia from 2003 to 2017.

448

449 Figure 2. The percentage of opioid users among NH and ALF residents with and without dementia
450 from 2003 to 2017.

451

452 Figure 3. Mean number of sedatives used by NH and ALF residents with and without dementia
453 from 2003 to 2017.